Literature DB >> 23959050

Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?

Chien-Hong Chiu, Yin-Kai Chao, Hsien-Kun Chang, Chen-Kan Tseng, Sheng-Chieh Chan, Yun-Hen Liu, Wei-Hsun Chen.   

Abstract

BACKGROUND: Although esophagectomy traditionally is recommended to perform within 8 weeks after neoadjuvant chemoradiotherapy (nCRT), data from neoadjuvantly treated rectal cancer patients demonstrate that delayed surgery ([8 weeks) can maximize the effect of CRT. Despite these promising data, investigators are concerned that delayed surgery may lead to tumor repopulation. We report the impact of delayed surgery in patients with esophageal cancer who were treated with nCRT.
METHODS: We retrospectively studied 276 esophageal cancer patients treated with nCRT and surgery between 2002 and 2008. We compared perioperative complication, rate of pathological complete response (pCR), distribution of tumor regression grade (TRG), and overall survival (OS) in patients who underwent surgery within 8 weeks (group A) and after 8 weeks (group B) after nCRT.
RESULTS: There were 138 patients in each group with similar pre/post-nCRT characteristics. Delayed surgery did not result in lower surgical risk or higher pCR rate. Survival outcome also did not improve following a longer surgery interval (5-year OS: group A vs. group B, 29 vs. 23 %; P = 0.3). On the contrary, a subgroup analysis showed that delayed surgery might be hazardous, especially in patients who demonstrate a good response after nCRT. The amount of residual cancer, as measured by TRG, increased significantly after a longer surgical interval (P = 0.024). Survival also decreased after a longer surgical interval (5-year OS B8 vs. [8 weeks, 50 vs. 35 %; P = 0.038).
CONCLUSIONS: After nCRT, esophagectomy should be performed within 8 weeks, especially in patients with good response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23959050     DOI: 10.1245/s10434-013-3139-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  [Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].

Authors:  A-K Müller; C Lenschow; D Palmes; N Senninger; R Hummel; K Lindner
Journal:  Chirurg       Date:  2015-09       Impact factor: 0.955

2.  Saving time is saving lives: a delayed lobectomy predicts poorer overall survival in patients with clinical stage IA squamous cell carcinoma of the lung.

Authors:  Ching Feng Wu; Yin-Kai Chao
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

3.  The effect of time interval on esophagectomy after neoadjuvant treatment.

Authors:  Lieven Depypere
Journal:  Ann Transl Med       Date:  2016-03

Review 4.  Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management.

Authors:  Masahiko Ikebe; Masaru Morita; Manabu Yamamoto; Yasushi Toh
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-10

5.  Effect of time to surgery on outcomes in stage I esophageal adenocarcinoma.

Authors:  Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Chi-Fu J Yang; Hanghang Wang; David H Harpole; Thomas A D'Amico
Journal:  J Thorac Cardiovasc Surg       Date:  2019-10-08       Impact factor: 5.209

6.  Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer.

Authors:  Talha Shaikh; Karen Ruth; Walter J Scott; Barbara A Burtness; Steven J Cohen; Andre A Konski; Harry S Cooper; Igor Astsaturov; Joshua E Meyer
Journal:  Ann Thorac Surg       Date:  2014-11-18       Impact factor: 4.330

7.  Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics.

Authors:  Hao Zhang; Shan Tan; Wengen Chen; Seth Kligerman; Grace Kim; Warren D D'Souza; Mohan Suntharalingam; Wei Lu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-01       Impact factor: 7.038

8.  Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer.

Authors:  Yong-Hyub Kim; Sang-Yun Song; Hyun-Jeong Shim; Woong-Ki Chung; Sung-Ja Ahn; Mee Sun Yoon; Jae-Uk Jeong; Ju-Young Song; Taek-Keun Nam
Journal:  Radiat Oncol J       Date:  2015-03-31

Review 9.  Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review.

Authors:  Xiao-Feng Duan; Peng Tang; Zhen-Tao Yu
Journal:  Cancer Biol Med       Date:  2014-09       Impact factor: 4.248

10.  Down-staging following neoadjuvant chemo-radiotherapy for locally advanced rectal cancer: Does timing of surgery really matter?

Authors:  Bhawna Sirohi; Savio George Barreto; Shraddha Patkar; Alok Gupta; Ashwin DeSouza; Sanjay Talole; Kedar Deodhar; Nitin Shetty; Reena Engineer; Mahesh Goel; Shailesh V Shrikhande
Journal:  Indian J Med Paediatr Oncol       Date:  2014-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.